Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Fujifilm’s Next-Generation Technology Doubles Antibody Productivity, Reduces Production Time by 30%
January 11, 2019
- NanoCarrier Submits CTA in EU for PII Study of NC-6004-Keytruda Combo for Head and Neck Cancer
January 11, 2019
- Daiichi Sankyo, Tokyo Institute of Technology Launch Open Innovation Research for Type 1 Diabetes Treatment Using iPS Cells
January 11, 2019
- Opdivo Extends OS in Second-Line Esophageal Cancer
January 10, 2019
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
- Kowa, Nissan Chemical Win US Patent Case over Livalo Crystal Form
January 10, 2019
- Meiji to Set Up JV with Canadian Firm to Develop Novel β-lactamase Inhibitor
January 9, 2019
- Eisai Recalls Azeptin after It Fails Dissolution Tests
January 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Fycompa Designated for Priority Review in China
January 9, 2019
- Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
- Kyowa Kirin Files Burosumab in Japan
January 8, 2019
- Takeda Revving Up Collaboration Efforts on I/O Front
January 8, 2019
- Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug
January 8, 2019
- Fujifilm to Make 10 Billion Yen Capital Investment in Bio CDMO Business
January 8, 2019
- Kaken Licenses Systemic Sclerosis Treatment from Corbus in Japan
January 8, 2019
- J-TEC’s Cell Sheet JACE Approved for Epidermolysis Bullosa
January 8, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…